Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppression withdrawal or minimization after liver transplantation
2017-004983-37Phase 3Active
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Jul 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus, cyclosporine, prednisone and mycophenolate mofetil in liver transplant (2 arms), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoints: Liver function parameters, Immunosuppressant drug levels and 1 more. Started Jul 2018; status: active.
02
Drugs
tacrolimuscyclosporineprednisonemycophenolate mofetil
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2017-004983-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004983-37.